What it is
Orforglipron is Eli Lilly's once-daily GLP-1 pill. It is not a peptide. It is a small synthetic molecule that happens to switch on the same receptor as semaglutide, which is why it can be swallowed as a normal tablet instead of injected. It is covered here because it competes directly with the peptide GLP-1 drugs and is one of the most searched names in the class.
The US FDA approved it on 1 April 2026 under the brand name Foundayo, for adults with obesity, or overweight with at least one weight-related condition, alongside diet and exercise.
How it works
Peptide GLP-1 drugs such as semaglutide and liraglutide are chains of amino acids. Stomach acid and digestive enzymes break peptides down, so oral semaglutide (Rybelsus) needs an absorption enhancer and strict fasting rules. Orforglipron sidesteps that problem entirely: as a small molecule it is absorbed like most tablets, and the label allows it with or without food.
Once absorbed, the effect is the familiar GLP-1 one: slower stomach emptying, more glucose-dependent insulin release, and reduced appetite through the brain. The label lists a half-life of about 29 to 49 hours, long enough for once-daily dosing.
One practical note on numbers: the published trial papers describe doses of 3, 6, 12 and 36 mg, while the FDA label lists tablet strengths from 0.8 mg to 17.2 mg. Lilly's 2026 releases report the top trial dose's results under the 17.2 mg strength. When reading any source, check which convention it uses.
What the research found
All of the key data comes from Lilly's phase 3 programmes in humans: ATTAIN for obesity and ACHIEVE for type 2 diabetes.
ATTAIN-1 (NEJM, 2025). 3,127 adults with obesity or overweight and no diabetes, 72 weeks. Among those who stayed on treatment, mean weight loss was 7.8% on 6 mg, 9.3% on 12 mg and 12.4% on 36 mg, versus 0.9% on placebo. Counting everyone randomised, the figures were 7.5%, 8.4% and 11.2% versus 2.1%.
ACHIEVE-1 (NEJM, 2025). 559 adults with type 2 diabetes and a starting A1C of 8.0%, 40 weeks. A1C fell by 1.3 to 1.6 points across the three doses versus 0.1 on placebo. Weight fell by up to 7.3 kg on 36 mg versus 1.3 kg on placebo.
ACHIEVE-3 (The Lancet, 2026). A 52-week head-to-head against oral semaglutide in 1,698 adults with type 2 diabetes. A1C fell 1.9 points on orforglipron 12 mg and 2.2 on 36 mg, versus 1.1 on oral semaglutide 7 mg and 1.4 on 14 mg. Weight loss was 6.7% and 9.2% on orforglipron versus 3.7% and 5.3% on oral semaglutide.
Lilly reported further diabetes trials in June 2026 (ACHIEVE-2 against dapagliflozin and ACHIEVE-5 in people on insulin) and said it would file for the type 2 diabetes indication in the US.
The honest summary: orforglipron works, and it beat the only other oral GLP-1 on the market in a direct trial. Its weight loss in ATTAIN-1 is smaller than injectable semaglutide and tirzepatide reported in their own trials. Its selling point is convenience, not maximum effect. See oral vs injectable peptides for why the delivery route matters.
Side effects reported in studies
Gastrointestinal effects led, as with every GLP-1 drug. In ATTAIN-1 at 36 mg versus placebo: nausea 33.7% versus 10.4%, constipation 25.4% versus 9.3%, diarrhoea 23.1% versus 9.6%, vomiting 24.0% versus 3.5%. Discontinuation because of adverse events was 5.3%, 7.9% and 10.3% on the three doses versus 2.7% on placebo.
The FDA label carries the class boxed warning on thyroid C-cell tumours seen in rodents, and warnings on pancreatitis, severe GI reactions, kidney injury from dehydration, gallbladder disease, hypoglycaemia with other diabetes drugs, and aspiration during anaesthesia. It also tells people on oral contraceptives to add a barrier method for 30 days after starting and after each dose increase.
Orforglipron vs oral semaglutide
| Orforglipron (Foundayo) | Oral semaglutide (Rybelsus) | |
|---|---|---|
| Molecule | Small molecule | Peptide with absorption enhancer |
| Food rules | With or without food | Taken fasting, before food |
| Head-to-head A1C, 52 wk (ACHIEVE-3) | Down 2.2 points (36 mg) | Down 1.4 points (14 mg) |
| Head-to-head weight, 52 wk | Down 9.2% (36 mg) | Down 5.3% (14 mg) |
| PH status | No registration identified | No verified PH price |
Status in the Philippines
No FDA Philippines registration for orforglipron or Foundayo had been identified as of September 2026. Lilly says it has submitted the drug in more than 40 countries, but until it is registered here it cannot be sold legally, and anything marketed locally as "orforglipron" is unregistered product. Because it is a tablet rather than a peptide, research-market versions carry the same identity questions as any unregulated pill.
GLP-1 medicines already sold in Philippine pharmacies include Ozempic, Wegovy, Mounjaro, Victoza and Saxenda. Prescribing belongs with a licensed Philippine physician. Pen prices are on cost reality in the Philippines.
Storage
The US label says to store tablets at room temperature, 20 to 25°C, with short excursions allowed between 15 and 30°C. Manila rooms without air-conditioning routinely run above 30°C, so a cool interior cupboard is a better spot than a car, bag or sunny shelf.
